Literature DB >> 17684772

[Cancer pain management. Basic therapy and treatment of breakthrough pain].

F Nauck1, N Eulitz.   

Abstract

Cancer pain imposes a great burden on patients and results in considerable constraints limiting their quality of life. The basic treatment for chronic pain consists in oral administration of long-acting preparations of various analgesic agents according to a set schedule. In addition to chronic pain, however, about 60% of cancer patients also suffer from breakthrough pain. Rapid-onset and short-acting preparations of highly potent opioids are available for the management of these attacks. To choose the correct analgesic agent, it is essential to take a comprehensive medical history and be aware of the different forms of pain present.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684772     DOI: 10.1007/s00482-007-0572-1

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.629


  24 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord.

Authors:  P Honore; N M Luger; M A Sabino; M J Schwei; S D Rogers; D B Mach; P F O'keefe; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice.

Authors:  G Zeppetella; C A O'Doherty; S Collins
Journal:  J Pain Symptom Manage       Date:  2000-08       Impact factor: 3.612

Review 4.  Bisphosphonates for controlling pain from metastatic bone disease.

Authors:  K M Diener
Journal:  Am J Health Syst Pharm       Date:  1996-08-15       Impact factor: 2.637

5.  Validation of the German version of the Brief Pain Inventory.

Authors:  L Radbruch; G Loick; P Kiencke; G Lindena; R Sabatowski; S Grond; K A Lehmann; C S Cleeland
Journal:  J Pain Symptom Manage       Date:  1999-09       Impact factor: 3.612

Review 6.  The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.

Authors:  Elizabeth Rees
Journal:  Int J Palliat Nurs       Date:  2002-06

Review 7.  Clinical pharmacokinetics of morphine.

Authors:  Ralph A Lugo; Steven E Kern
Journal:  J Pain Palliat Care Pharmacother       Date:  2002

Review 8.  Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany.

Authors:  Lukas Radbruch; Frank Elsner
Journal:  Keio J Med       Date:  2004-03

9.  Absorption and bioavailability of oral transmucosal fentanyl citrate.

Authors:  J B Streisand; J R Varvel; D R Stanski; L Le Maire; M A Ashburn; B I Hague; S D Tarver; T H Stanley
Journal:  Anesthesiology       Date:  1991-08       Impact factor: 7.892

10.  Use of strong opioids in advanced cancer pain: a randomized trial.

Authors:  Franco Marinangeli; Alessandra Ciccozzi; Marco Leonardis; Luca Aloisio; Anna Mazzei; Antonella Paladini; Giampiero Porzio; Paolo Marchetti; Giustino Varrassi
Journal:  J Pain Symptom Manage       Date:  2004-05       Impact factor: 3.612

View more
  6 in total

1.  [Cancer pain in palliative medicine].

Authors:  R Laufenberg-Feldmann; R Schwab; R Rolke; M Weber
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

Review 2.  [Cancer pain in palliative medicine].

Authors:  R Laufenberg-Feldmann; R Schwab; R Rolke; M Weber
Journal:  Anaesthesist       Date:  2012-05       Impact factor: 1.041

3.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

4.  [Cancer pain therapy in palliative care patients: knowledge of prehospital emergency physicians in training. Prospective questionnaire-based investigation].

Authors:  C H R Wiese; E K Löffler; J Vormelker; N Meyer; M Taghavi; M Strumpf; S Kazmaier; M Roessler; Y A Zausig; A F Popov; C L Lassen; B M Graf; G G Hanekop
Journal:  Schmerz       Date:  2010-09       Impact factor: 1.107

5.  [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].

Authors:  S Wirz; C H R Wiese; M Zimmermann; U Junker; E Heuser-Grannemann; M Schenk
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

6.  Matrix stimulation in cancer pain: Methodology, safety and effectiveness.

Authors:  M Mücke; M Tils; R Conrad; D Kravchenko; H Cuhls; L Radbruch; M Marinova; V Peuckmann-Post; R Rolke
Journal:  Eur J Pain       Date:  2017-08-14       Impact factor: 3.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.